Results 71 to 80 of about 13,745 (204)

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients

Drug Design, Development and Therapy, 2010
John PuetzSaint Louis University, Department of Pediatrics, St Louis, Missouri, USAAbstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia is the development of inhibitors. Alloantibodies or autoantibodies directed
John Puetz
doaj  

The effect of perioperative erythropoietin‐stimulating agents and intravenous iron on patient outcomes following solid organ transplantation: A systematic review

Transfusion Medicine, Volume 36, Issue 2, Page 95-120, April 2026.
Abstract Solid organ transplant is associated with high rates of anaemia and transfusion, but there is little comparative data on interventions such as erythropoietin‐stimulating agents (ESAs) and intravenous (IV) iron. We conducted a systematic review examining the association of ESAs and IV iron with outcomes in adults undergoing solid organ ...
Frank Lee, Quentin Eichbaum, Christine Cserti‐Gazdewich, Darren Mullane, Frederick W. Lombard, Jeremy W. Jacobs, Katerina Pavenski, Marina Englesakis, Alexander Dotto, Terry Cho, Andrés Leonard‐Reixa, Jacqueline Trudeau, Andrew W. Shih, Justyna Bartoszko   +13 more
wiley   +1 more source

Sequential therapy: an option for hemophiliac patients not responding to monotherapy with bypassing agents. Observational study of the GrHeCol (Grupo Hemofilia Colombia)

Iatreia, 2018
Introduction and objectives: Patients diagnosed with severe hemophilia are at risk of developing inhibitors of low or high title, being the treatment of choice for this latter group of patients the immune tolerance therapy (ITI).
Casas, Claudia Patricia, Sossa, Claudia Lucía, Linares, Adriana, Omaña-Orduz, Olga Paola, Peña, Ángela María, Solano, María Helena   +5 more
doaj   +1 more source

Filamin-A is required for the incorporation of tissue factor into cell-derived microvesicles [PDF]

, 2013
We previously reported that the incorporation of tissue factor (TF) into cell-derived microvesicles (MVs) is regulated by the phosphorylation of the cytoplasmic domain of TF.
Collier, Mary E. W., Ettelaie, Camille, Maraveyas, Anthony   +2 more
core   +1 more source

Vascular miR‐181b controls tissue factor‐dependent thrombogenicity and inflammation in type 2 diabetes [PDF]

, 2020
BACKGROUND: Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (
Chakraborty, Aritra, Dörner, Andrea, Friebel, Julian, Krueger, Andreas, Landmesser, Ulf, Rauch, Ursula, Ruf, Wolfram, Saffarzadeh, Mona, Stratmann, Bernd, Ta Bao, Loc, Tabaraie, Termeh, Tschoepe, Diethelm, Winter, Samantha J., Witkowski, Marco, Witkowski, Mario   +14 more
core   +1 more source

Co‐localization of tau and TDP‐43 after extracellular vesicle delivery to cells

The FEBS Journal, Volume 293, Issue 5, Page 1495-1515, March 2026.
Extracellular vesicles (EVs) derived from donor cells transfected with EGFP–2N4R‐tau or mCherry‐wtTDP‐43 were taken up by recipient cells, leading to cytosolic co‐localization of tau and TDP‐43. Molecular modeling revealed that tau and TDP‐43 directly interact through hydrogen bonding, suggesting a mechanistic link underlying their co‐pathology ...
Farhang Aliakbari, Kathryn Volkening, Zahra Nayeri, Aysegul Yucel Polat, Neil Donison, Jacqueline Palik, Michael J. Strong   +6 more
wiley   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

4‐(5‐Chloro‐3‐(3,4,5‐trimethoxybenzoyl)‐1H‐indol‐1‐yl)benzenesulfonamide: A Novel Polypharmacology Agent to Target Carbonic Anhydrase IX and XII With Improved Selectivity, Wnt/β‐Catenin Signaling Pathway, and P‐Glycoprotein

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
Polypharmacology is expected to produce higher therapeutic efficacy and lower cytotoxic and side effects. Compound 15 exhibited strong inhibition of the human carbonic anhydrase isoforms IX and XII and selectivity toward the adverse isoforms I and II.
Michela Puxeddu, Rosa Bordone, Claudia Colla, Gabriele Rotili, Antonio Coluccia, Pietro Sciò, Petra Cuřínová, Alessio Nocentini, Claudiu T. Supuran, Serena Filiberti, Marta Turati, Roberto Ronca, Joanna Kopecka, Chiara Riganti, Lucia Jimenez, Wolfgang Link, Chiara Bigogno, Giulio Dondio, Martina Barba, Gianluca Canettieri, Romano Silvestri, Giuseppe La Regina   +21 more
wiley   +1 more source

Successful Hemostasis with Recombinant Activated Factor VII in a Patient with Massive Hepatic Subcapsular Hematoma

Case Reports in Gastroenterology, 2009
Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the management of acquired deficiencies of factor VII and platelet function defects.
Ju-Hee Lee, Hee Bok Chae, Eui-Keun Seo, Won Joong Jeon, Hye Won Jeong, Yoon Mi Shin, Jang Whan Bae, Soon Kil Kwon, Il Hun Bae, Woo Sub Shim, Dong Ick Shin, Rohyun Sung, Ji Yoon Kim   +12 more
doaj   +1 more source

The use of recombinant activated factor VIIa for major bleedings in open heart surgery [PDF]

, 2008
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenINTRODUCTION: We evaluated the efficacy of activated recombinant factor VIIa (rFVIIa) administration for critical bleeding during cardiothoracic surgery in ...
Brynjar Viðarsson, Felix Valsson, Jóhann Páll Ingimarsson, Páll T. Önundarson, Tómas Guðbjartsson   +4 more
core